Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
ELSPAR |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Enzyme. |
| Generic Name |
|
Asparaginase 10,000 IU/vial; pwd for IV or IM injection after reconstitution; contains mannitol; preservative-free. |
| Indications |
|
Adjunct in acute lymphoblastic leukemia. |
| Adults and Children |
|
Give by IV inj over at least 30 minutes or by IM inj (max 2mL/inj site). 6000 IU/m2 IM or IV three times per week. |
| Contraindications |
|
Pancreatitis, serious hemorrhage, or thrombosis with prior use. |
| Precautions |
|
Have resuscitation equipment available and observe for 1 hour post-dosing. Monitor blood counts, PT/INR, glucose, and hepatic function; and for pancreatitis (serum amylase, abdominal pain). Discontinue if serious allergic reactions, thrombotic events, or pancreatitis occurs. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, CNS thrombosis, coagulopathy, hyperbilirubinemia, elevated transaminases. |
| How Supplied |
|
Single-use vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
